MesenCure

BIOLOGICAL2 trials

Sponsors

BonusBio Group Ltd

Conditions

ARDSCovid19

Phase 1

Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19

CompletedNCT04716998

BonusBio Group LtdCovid19

Start: 2021-01-14End: 2022-01-31Updated: 2025-08-12

Phase 3

A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With ARDS

Not yet recruitingNCT05497401

BonusBio Group LtdARDS

Start: 2026-04-30End: 2028-10-31Target: 300Updated: 2025-08-11